Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker

By LabMedica International staff writers
Posted on 13 Nov 2026
Rheumatic heart disease (RHD) causes hundreds of thousands of deaths annually, disproportionately affecting children and young adults in low- and middle-income countries. More...
Early detection remains challenging in resource-limited settings, where specialized ultrasound equipment, laboratory infrastructure, and refrigerated antibody-based tests are often unavailable. To help overcome these barriers, researchers have developed an antibody-free blood-testing approach designed to detect cardiac inflammatory biomarkers without complex laboratory equipment.
 
Researchers at Ben-Gurion University of the Negev (BGU; Beersheba, Israel) developed a synthetic, antibody-free diagnostic probe for detecting rheumatic heart disease (RHD)-related biomarkers in blood. The polymer-based sensor uses an HPMA backbone modified with specific peptide ligands and near-infrared fluorescent dyes. By eliminating the need for biological antibodies, which are costly to produce and sensitive to heat degradation, the technology aims to support rapid point-of-care screening in rural and underserved communities.
 
The probe functions as an optical switch that generates a fluorescent signal when it encounters E-selectin, an adhesion molecule released into the bloodstream during active valvular inflammation. In its inactive state, the polymer remains tightly clustered, bringing the fluorescent dyes close enough to suppress their light emission. When the targeting peptides bind to E-selectin, the polymer uncoils, separating the dyes and triggering a measurable fluorescent signal detectable using standard microplate readers.
 
In laboratory testing, the probe successfully detected and quantified E-selectin directly in complex serum samples, producing a clear, dose-dependent fluorescent response. Current detection sensitivity is in the microgram range, with further optimization underway to achieve nanogram-level detection for early-stage disease assessment. The findings were published in ACS Sensors, with researchers from BGU, Massachusetts General Hospital, and Harvard Medical School contributing to the study.
 
Although no established blood biomarker currently exists for diagnosing RHD, researchers suggest that combining multiple biomarkers could help distinguish the disease from non-rheumatic valvular conditions and other inflammatory disorders. The same polymer platform could also be adapted to detect biomarkers associated with other vascular and inflammatory diseases by modifying its targeting peptides, potentially expanding its diagnostic applications.
 
“Current diagnostics depend heavily on delicate animal-derived antibodies that spoil if they aren't kept on ice. By replacing antibodies with robust synthetic polymers and peptides, we have created a platform that is inherently stable, significantly cheaper to manufacture and resilient to ambient temperatures. It is built specifically to survive real-world conditions where cold-chain logistics simply don't exist,” said professor Ayelet David, lead researcher at Ben-Gurion University of the Negev.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Guardant Health has introduced new applications for Guardant360 Liquid, expanding the test’s capabilities for treatment selection in breast and lung cancers. (Photo courtesy of Guardant Health)

Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations

Treatment selection in advanced breast and lung cancers can be challenging when traditional biomarkers are absent and genomic findings alone do not fully clarify which therapies may be effective.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.